• Here we show that the co activation of RTKs

  2023-05-17

  

  Here, we show that the co-activation of RTKs and non-RTKs is a common trait in treatment-naïve EGFR-mutation-positive NSCLC Mifepristone and patients, with AXL and CDCP1 being commonly over-expressed. The combination of gefitinib or osimertinib with the Src/FAK/Janus kinase 2 (JAK2) inhibitor TPX-00

• Protein phosphorylation is an important posttranslational

  2023-05-17

  

  Protein phosphorylation is an important posttranslational mechanism for the regulation of distribution, trafficking, and function of modified proteins (Wang et al., 2014). GluA1 phosphorylation at S845 also has functional consequences (Lu and Roche, 2012). For instance, S845 phosphorylation drove tr

• br Acknowledgements This work was supported by the Victorian

  2023-05-17

  

  Acknowledgements This work was supported by the Victorian Government Operational Infrastructure Support Program. KAB is supported by the Mavis Robertson Fellowship from the National Breast Cancer Foundation (NBCF; ECF-16-004), by an NBCF Novel Concept Award (NC-14-011), and by NHMRC project grant

• AP activity is increased by MAP kinase

  2023-05-17

  

  AP-1 activity is increased by MAP kinase stimulation in different cell types (Whitmarsh and Davis, 1996), while MKP-1, the enzyme that catalyzes the dephosphorylation and inactivation of MAP kinases in the nucleus, inhibits AP-1 (Rössler et al., 2008, Rössler and Thiel, 2009, Mayer et al., 2011, Thi

• br Materials and methods br Results br Discussion Diabetic

  2023-05-17

  

  Materials and methods Results Discussion Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease [15], [16]. The pathogenesis of DKD is not fully understood, and there is no effective treatment. Although previous studies suggested that early lesions of DKD are foun

• br Implementation of sacubitril valsartan into clinical

  2023-05-17

  

  Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio

• We also found that the size

  2023-05-17

  

  We also found that the size of mEPSC amplitude was reduced in unc-43 mutants, consistent with the decrease in synaptic GLR-1/GLR-2 heteromeric receptors. The decrease in mEPSC amplitude was not as great as that observed when measuring current in response to pressure application of glutamate. These d

• In young animals the HT A receptor antagonist ketanserin

  2023-05-15

  

  In young animals, the 5-HT2A Tideglusib antagonist ketanserin, at relatively low concentrations, shifted 5-HT concentration-response curves rightward, suggesting a role for 5-HT2A receptors in mediating 5-HT-induced contractions of the ureter. The slopes of the ketanserin Schild plots for the antago

• Adenosine receptors are proposed to play proangiogenic role

  2023-05-15

  

  Adenosine receptors are proposed to play proangiogenic role in vascular and immune MM-102 within microenvironment of hypoxic tissues to maintain tissue oxygenation in chronic ischemic condition [9]. Adenosine also stimulates the production of angiopoetin-1, VEGF and Interleukin-6 (IL6) via adenosine

• With the treatment options available today including

  2023-05-15

  

  With the treatment options available today including a combination of symptomatic treatments and general immunosuppression, many MG patients can lead productive lives [1], [4], [20]. The frequency of death has decreased due to improved management and detection of milder cases. At present, the overal

• Additional evidence for a putative role of COXs

  2023-05-15

  

  Additional evidence for a putative role of COXs and 5-LOX in AD derives from pharmacological studies using inhibitors of these enzymes (for review, see Firuzi and Praticò, 2006). In addition to helping delineate the pathobiological mechanisms of AD, these results raise hope for discovering novel the

• ci-1033 MLN another selective Aurora A inhibitor

  2023-05-15

  

  MLN8237, another selective Aurora-A inhibitor is said to be more potent than MLN8054 and to cause less benzodiazepine-like side effects based on structure modulation by the addition of a methoxy group to either end of the MLN8054 molecule. It was studied [62] in a once daily (QD) schedule for 7 days

• Recent studies have demonstrated significant cross talk

  2023-05-15

  

  Recent studies have demonstrated significant cross-talk between XRCC1 (a key player in ikk inhibitor excision repair (BER) and single strand break repair) and DDR [30], [31], [32]. ATM and DNA-PKcs are known to be involved in the phosphorylation of XRCC1 to promote BER [30], [31]. We have recently

• 78 4 This suggestion was confirmed by immunohistochemical st

  2023-05-15

  

  This suggestion was confirmed by immunohistochemical studies in which the immunoreactivity of the enzyme was actually higher at the earlier rather than at the advanced stages of the disease. Importantly, a later study showed that the biochemical signature of 12/15LO enzymatic activation (i.e., 12-HE

• br Results and discussion br Conclusion The tyrosine

  2023-05-15

  

  Results and discussion Conclusion The tyrosine kinase ALK represents one of the most successful molecular targets for the development of precise medicine to treat stratified subgroups of cancer patients. Three generations of ALK inhibitors have been awarded the FDA's approval or are being exte

15701 records 337/1047 page Previous Next First page 上5页 336337338339340 下5页 Last page